U.S. markets open in 5 hours 56 minutes
  • S&P Futures

    -0.50 (-0.01%)
  • Dow Futures

    +58.00 (+0.18%)
  • Nasdaq Futures

    -61.00 (-0.46%)
  • Russell 2000 Futures

    +13.40 (+0.59%)
  • Crude Oil

    +0.47 (+0.74%)
  • Gold

    -10.00 (-0.56%)
  • Silver

    -0.01 (-0.05%)

    +0.0028 (+0.23%)
  • 10-Yr Bond

    0.0000 (0.00%)
  • Vix

    -1.37 (-5.93%)

    +0.0004 (+0.03%)

    +0.1980 (+0.19%)

    +287.60 (+0.58%)
  • CMC Crypto 200

    +5.90 (+0.59%)
  • FTSE 100

    +13.01 (+0.20%)
  • Nikkei 225

    +496.57 (+1.67%)

Free Research Report as Danaher’s Quarterly Revenues Jumped 11.5%; Adjusted EPS Advanced 16.5%

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Stock Monitor: Gorman-Rupp Post Earnings Reporting

LONDON, UK / ACCESSWIRE / May 03, 2018 / Active-Investors.com has just released a free earnings report on Danaher Corp. (NYSE: DHR). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=DHR. The Company reported its first quarter fiscal 2018 operating and financial results on April 19, 2018. The industrial and medical device maker outperformed top- and bottom-line expectations. Additionally, the Company raised its adjusted earnings guidance for FY18. Register today and get access to over 1000 Free Research Reports by joining our site below:


Active-Investors.com is currently working on the research report for The Gorman-Rupp Company (NYSE: GRC), which also belongs to the Industrial Goods sector as the Company Danaher. Do not miss out and become a member today for free to access this upcoming report at:


Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Danaher most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:


Earnings Highlights and Summary

For the first quarter of the fiscal year 2018, Danaher's revenues increased 11.5% to $4.7 billion on a y-o-y basis compared to $4.2 billion in Q1 2017, due to the impact of currency translation increasing revenues by 5% and acquisitions adding 1%. Danaher's core revenues were up 5.5% on a y-o-y basis, with four of its five platforms delivering mid-single-digit or better core growth. The Company's revenue numbers topped analysts' estimates of $4.6 billion.

During Q1 2018, Danaher's gross margin was 56.3%, an all-time high, and was up 80 basis points compared to the year ago same period. The Company's core operating margin expanded 140 basis points.

For the quarter ended March 30, 2018, Danaher's net earnings were $566.6 million, or $0.80 per diluted share, compared to $506.1 million, or $0.72 per diluted share, in Q1 2017.

Danaher's non-GAAP net diluted earnings per share (EPS) were $0.99, up 16.5% compared to $0.85 in Q1 2017, and beating Wall Street's estimates of $0.93.

Segment Results

During Q1 2018, Danaher's Life Sciences segment's reported revenues increased 13%, and core revenues grew 5.5%. The segment's reported operating profit margin was 18.4%, with both core and reported margins increasing over 200 basis points. This marked the seventh consecutive quarter of more than 100 basis points of core margin improvement in the segment.

For Q1 2018, Danaher's Diagnostics segment's reported revenues grew 14.5%, and core revenues increased 9.5%. The segment's reported operating profit margin increased to 16.3%, with both core and reported margins up 470 basis points; largely attributable to higher sales volumes and cost savings derived from productivity initiatives implemented in FY17. Within the Diagnostics segment, the Cepheid unit's core revenues surged 40% on a y-o-y basis, driven by a combination of good commercial execution, test menu expansion, and a particularly challenging flu season.

During Q1 2018, Danaher's Dental segment's reported revenues rose 2.5%, while core revenues were down 3%. The segment's operating profit margin declined to 7.6%, largely due to lower sales volume, continued investment spends, and productivity initiatives across the platform.

For Q1 2018, Danaher's Environmental and Applied Solutions segment's reported revenues grew 12.5%, with core revenues up 4.5%. The segment's core operating margin increased by 15 basis points and reported operating margin declined 60 basis points to 22.1%.

Cash Matters

During Q1 2018, Danaher's operating cash flow was $828.9 million, representing an increase of 48% compared to $560.2 million in Q1 2017. The Company's free cash flow soared 72% to $691.4 million on a y-o-y basis in the reported quarter, representing a non-GAAP free cash flow to net income conversion ratio of 122% for Q1 2018.


For the second quarter of the fiscal year 2018, Danaher is forecasting GAAP net diluted EPS to be in the range of $0.88 to $0.91, and non-GAAP net diluted EPS to be in the band of $1.07 to $1.10.

For the full fiscal year 2018, Danaher is projecting net EPS to be in the range of $3.62 to $3.69. The Company is now estimating non-GAAP net EPS to be in the band of $4.38 to $4.45 for FY18 versus the previous guidance of $4.25 to $4.35.

Stock Performance Snapshot

May 02, 2018 - At Wednesday's closing bell, Danaher's stock dropped 1.32%, ending the trading session at $99.56.

Volume traded for the day: 1.96 million shares.

Stock performance in the last month – up 1.35%; previous six-month period – up 8.44%; past twelve-month period – up 19.95%; and year-to-date – up 7.26%

After yesterday's close, Danaher's market cap was at $68.75 billion.

Price to Earnings (P/E) ratio was at 27.56.

The stock has a dividend yield of 0.64%.

The stock is part of the Industrial Goods sector, categorized under the Diversified Machinery industry.


Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.


For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors